{"id":483170,"date":"2020-05-07T22:16:01","date_gmt":"2020-05-07T22:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=483170"},"modified":"2020-05-07T22:16:01","modified_gmt":"2020-05-07T22:16:01","slug":"hepatic-encephalopathy-market-insight-epidemiology-and-market-forecast-2028","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hepatic-encephalopathy-market-insight-epidemiology-and-market-forecast-2028_483170.html","title":{"rendered":"Hepatic Encephalopathy Market Insight, Epidemiology and Market Forecast – 2028"},"content":{"rendered":"
\"Hepatic<\/a><\/p>\n
\n
DelveInsight<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘Hepatic Encephalopathy Market Insight, Epidemiology and Market Forecast – 2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Hepatic Encephalopathy in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan. <\/div>\n

Hepatic Encephalopathy Market Insights, Epidemiology and Market Forecast-2028<\/a><\/p>\n

(Albany, US) <\/span>DelveInsight launched a new report on Hepatic Encephalopathy Market Insights, Epidemiology and Market Forecast-2028<\/a><\/p>\n

Some of the key facts of the report<\/span>
1. Hepatic Encephalopathy is a prevalent complication of liver disease and occurs in approximately 30–45% of patients with cirrhosis and 10–50% of patients with a transjugular intrahepatic portosystemic shunt.<\/span>
2. Overt Hepatic Encephalopathy (HE) will occur in 30%-40% of those with cirrhosis at some time during their clinical course and the survivors in most cases repeatedly. Minimal HE (MHE) or covert HE (CHE) occurs in 20%-80% of patients with cirrhosis.<\/span><\/p>\n

Key benefits of the report<\/span>
1. Hepatic Encephalopathy market report covers a descriptive overview and comprehensive insight of the Hepatic Encephalopathy epidemiology and Hepatic Encephalopathy market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span>
2. Hepatic Encephalopathy market report provides insights on the current and emerging therapies.<\/span>
3. Hepatic Encephalopathy market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. Hepatic Encephalopathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hepatic Encephalopathy market.<\/span><\/p>\n

Request for sample pages<\/a><\/p>\n

\"\"<\/a><\/p>\n

\n

The goal of Hepatic Encephalopathy treatment includes identification and removal of precipitating factors, reduction of the nitrogenous load from the gut and assessment of the need for long term therapy. The current treatment of Hepatic Encephalopathy includes the use of nutritional management, bowel clearance, nonabsorbable disaccharides, antibiotics, sodium benzoate, branched-chain amino acids, dopamine agonists, probiotics and liver transplantation. Additional Hepatic Encephalopathy treatment for individuals is usually aimed at lowering the levels of ammonia and other toxins in the blood. Lactulose (Non-absorbable Disaccharides) is a first-line pharmacological Hepatic Encephalopathy treatment. Antibiotics are a therapeutic alternative to nonabsorbable disaccharides for the treatment of acute and chronic encephalopathy and cirrhosis.<\/span><\/p>\n

Currently, rifaximin, and lactulose, a synthetic sugar, are the standard of care for the disease. Hepatic Encephalopathy treatment remains a substantial unmet need, and a vast concerted effort is needed to define this condition better to allow the development of new therapies. Also, it is essential for the current treatments to be well understood and also to undergo controlled studies before their use on patients. Over recent years, many companies have shown interest in evaluating several potential therapeutic targets. Further progress in the research and development is likely to translate into a real improvement in the treatment options for Hepatic Encephalopathy patients and is likely to boost the revenue growth of Hepatic Encephalopathy therapeutics market in the forecast period.<\/span><\/p>\n

The launch of the emerging therapies is expected to significantly impact Hepatic Encephalopathy treatment scenario in the upcoming years:-<\/span>
Drugs covered<\/span>
1. SYNB-1020<\/span>
2. MNK6106<\/span>
And many others<\/span><\/p>\n

The key players in Hepatic Encephalopathy market are:<\/span>
1. Synlogic<\/span>
2. Mallinckrodt<\/span>
3. Aska Pharmaceuticals<\/span>
4. Wockhardt<\/span><\/p>\n

And many others<\/span><\/p>\n

Table of contents<\/span>
1. Report Introduction<\/span>
2. Hepatic Encephalopathy Market Overview at a Glance<\/span>
3. Hepatic Encephalopathy Disease Background and Overview<\/span>
4. Hepatic Encephalopathy Epidemiology and Patient Population<\/span>
5. Hepatic Encephalopathy Country- Wise Epidemiology<\/span>
5.1. United States<\/span>
5.2. EU-5<\/span>
5.3. Germany<\/span>
5.4. France<\/span>
5.5. Italy<\/span>
5.6. Spain<\/span>
5.7. United Kingdom<\/span>
5.8. Japan<\/span>
6. Hepatic Encephalopathy Treatments & Medical Practices<\/span>
7. Marketed Therapies<\/span>
7.1. Key Cross Competition<\/span>
7.2. Vabomere: The Medicines Company<\/span>
9. Hepatic Encephalopathy Emerging Therapies<\/span>
9.1. Key Cross Competition<\/span>
9.2. SYNB-1020:Wockhardt<\/span>
11. Hepatic Encephalopathy Market Size<\/span>
11.1. Key Findings<\/span>
11.2. Total 7MM Hepatic Encephalopathy Market Analysis<\/span>
11.3. Overview of Total Hepatic Encephalopathy Market<\/span>
11.4. Market size of Hepatic Encephalopathy by 7MM (2016-2027)<\/span>
11.5. 7MM Hepatic Encephalopathy: Country-Wise Market Analysis<\/span>
11.6. United States Market Size<\/span>
11.7. Germany Market Size<\/span>
11.8. France Market Size<\/span>
11.9. United Kingdom Market Size<\/span>
11.10. Spain Market Size<\/span>
11.11. Italy Market Size<\/span>
11.12. Japan Market Size<\/span>
12. Hepatic Encephalopathy Report Methodology<\/span>
13. DelveInsight Capabilities<\/span>
14. Disclaimer<\/span>
15. About DelveInsight<\/span><\/p>\n

About DelveInsight<\/span>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight DelveInsight’s ‘Hepatic Encephalopathy Market Insight, Epidemiology and Market Forecast – 2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Hepatic Encephalopathy in the United States, EU5 (Germany, Spain, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,404],"tags":[],"class_list":["post-483170","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=483170"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483170\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=483170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=483170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=483170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}